Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia

Alfonso Quintás-Cardama, Jorge Cortes

Research output: Contribution to journalReview article

Abstract

Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development of resistance continues to challenge the treatment of this disease. Mutations within the kinase domain of BCR-ABL1 constitute the most frequent mechanism of resistance in patients with chronic myelogenous leukemia treated with imatinib or the second generation tyrosine kinase inhibitors nilotinib and dasatinib. Of particular concern is the substitution of the threonine residue at the highly conserved gatekeeper residue 315 with a bulkier hydrophobic isoleucine amino acid. This mutation causes steric hindrance precluding the access ATP-competitive inhibitors to the ATP-binding pocket. To expedite the identification of strategies to override the resistance imposed by the T3151 mutation, several strategies have been pursued, including the exploitation of BCR-ABL1 kinase sites distant from the ATP-binding pocket to cripple the kinase activity of the enzyme and inhibiting signaling pathways downstream from BCR-ABL1. Recent insights gained regarding the structural biology of T315I have led to the development of a variety of compounds against this mutant. We herein summarize the most clinically promising anti-T3151 therapies.

Original languageEnglish (US)
Pages (from-to)4392-4399
Number of pages8
JournalClinical Cancer Research
Volume14
Issue number14
DOIs
StatePublished - Jul 15 2008
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phosphotransferases
Adenosine Triphosphate
Mutation
Isoleucine
Threonine
Protein-Tyrosine Kinases
Therapeutics
Amino Acids
Enzymes
Imatinib Mesylate

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. / Quintás-Cardama, Alfonso; Cortes, Jorge.

In: Clinical Cancer Research, Vol. 14, No. 14, 15.07.2008, p. 4392-4399.

Research output: Contribution to journalReview article

@article{d6e86c3977324ed99359a69ff95f09ea,
title = "Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia",
abstract = "Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development of resistance continues to challenge the treatment of this disease. Mutations within the kinase domain of BCR-ABL1 constitute the most frequent mechanism of resistance in patients with chronic myelogenous leukemia treated with imatinib or the second generation tyrosine kinase inhibitors nilotinib and dasatinib. Of particular concern is the substitution of the threonine residue at the highly conserved gatekeeper residue 315 with a bulkier hydrophobic isoleucine amino acid. This mutation causes steric hindrance precluding the access ATP-competitive inhibitors to the ATP-binding pocket. To expedite the identification of strategies to override the resistance imposed by the T3151 mutation, several strategies have been pursued, including the exploitation of BCR-ABL1 kinase sites distant from the ATP-binding pocket to cripple the kinase activity of the enzyme and inhibiting signaling pathways downstream from BCR-ABL1. Recent insights gained regarding the structural biology of T315I have led to the development of a variety of compounds against this mutant. We herein summarize the most clinically promising anti-T3151 therapies.",
author = "Alfonso Quint{\'a}s-Cardama and Jorge Cortes",
year = "2008",
month = "7",
day = "15",
doi = "10.1158/1078-0432.CCR-08-0117",
language = "English (US)",
volume = "14",
pages = "4392--4399",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia

AU - Quintás-Cardama, Alfonso

AU - Cortes, Jorge

PY - 2008/7/15

Y1 - 2008/7/15

N2 - Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development of resistance continues to challenge the treatment of this disease. Mutations within the kinase domain of BCR-ABL1 constitute the most frequent mechanism of resistance in patients with chronic myelogenous leukemia treated with imatinib or the second generation tyrosine kinase inhibitors nilotinib and dasatinib. Of particular concern is the substitution of the threonine residue at the highly conserved gatekeeper residue 315 with a bulkier hydrophobic isoleucine amino acid. This mutation causes steric hindrance precluding the access ATP-competitive inhibitors to the ATP-binding pocket. To expedite the identification of strategies to override the resistance imposed by the T3151 mutation, several strategies have been pursued, including the exploitation of BCR-ABL1 kinase sites distant from the ATP-binding pocket to cripple the kinase activity of the enzyme and inhibiting signaling pathways downstream from BCR-ABL1. Recent insights gained regarding the structural biology of T315I have led to the development of a variety of compounds against this mutant. We herein summarize the most clinically promising anti-T3151 therapies.

AB - Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development of resistance continues to challenge the treatment of this disease. Mutations within the kinase domain of BCR-ABL1 constitute the most frequent mechanism of resistance in patients with chronic myelogenous leukemia treated with imatinib or the second generation tyrosine kinase inhibitors nilotinib and dasatinib. Of particular concern is the substitution of the threonine residue at the highly conserved gatekeeper residue 315 with a bulkier hydrophobic isoleucine amino acid. This mutation causes steric hindrance precluding the access ATP-competitive inhibitors to the ATP-binding pocket. To expedite the identification of strategies to override the resistance imposed by the T3151 mutation, several strategies have been pursued, including the exploitation of BCR-ABL1 kinase sites distant from the ATP-binding pocket to cripple the kinase activity of the enzyme and inhibiting signaling pathways downstream from BCR-ABL1. Recent insights gained regarding the structural biology of T315I have led to the development of a variety of compounds against this mutant. We herein summarize the most clinically promising anti-T3151 therapies.

UR - http://www.scopus.com/inward/record.url?scp=51649120694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649120694&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-0117

DO - 10.1158/1078-0432.CCR-08-0117

M3 - Review article

C2 - 18628453

AN - SCOPUS:51649120694

VL - 14

SP - 4392

EP - 4399

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 14

ER -